Close Menu


Originally published Jan. 18.
EU's Committee for Medicinal Products for Human Use this week recommended that the European Medicine's Agency grant conditional marketing authorization for Pfizer's leukemia drug bosutinib.

Belgian diagnostics firm Pronota said this week that it would be participating in an international consortium funded by €6 million ($7.6 million) through the European Union's Seventh Framework Program to validate and refine its protein biomarker tests for preeclampsia.

Provided via the EU's Seventh Framework program, the grant will fund proteomics research to be performed by the PRIME-XS consortium, a group of proteomics research teams from 12 European institutes.

Biovista received $500,000 from the P-medicine project in Europe to use its Clinical Outcomes Search Space platform to analyze clinical trial data and identify new indications for cancer treatments.

European geneticists have had some success in blunting the impact of BRCA patents on their research, but the structure of the European patent system has barred them from broadly challenging gene patents in the way the ACLU and PUBPAT have in the US.

The EU extended its deadline to make a decision on the merger to Jan. 20.


A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.


University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.